Literature DB >> 3152975

Deferoxamine (Desferal)-induced ocular toxicity.

C Kaplinsky1, B Stark, Y Goshen, I Yaniv, S Bashara, R Zaizov.   

Abstract

A 4-year-old girl with juvenile chronic myeloid leukemia relapsed after an allogeneic bone marrow transplantation (BMT) and became refractory to conventional chemotherapy. Treatment with two courses of high-dose deferoxamine, an iron chelator (130-180 mg/kg/day), along with low-dose ARA-c (5 mg/kg/day) caused a remarkable decrease of the WBC and fetal Hb. Three days following the last dose of deferoxamine, the patient experienced an acute visual loss, confirmed by electroretinogram (ERG) and visual evoked response (VER). Slight improvement occurred a few days later, but the patient developed severe pancytopenia and died of Klebsiella septic shock. The ocular manifestations were attributed to deferoxamine toxicity in light of the rapid onset after first exposure, the electrophysiological pattern of metabolic damage in the ERG and VER, and the long interval between the last chemotherapy and BMT. The pathogenesis of deferoxamine toxicity is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3152975     DOI: 10.3109/08880018809037369

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

1.  Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.

Authors:  E E Voest; J P Neijt; J E Keunen; A W Dekker; B S van Asbeck; J W Nortier; F E Ros; J J Marx
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 2.  Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency.

Authors:  Kenneth A Myers; Ana Nikolic; Kenneth Romanchuk; Ezekiel Weis; Marie-Anne Brundler; Lucie Lafay-Cousin; Fiona Costello
Journal:  Neurooncol Pract       Date:  2016-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.